公开(公告)号：WO2023089032A1

公开(公告)日：2023-05-25

申请号：PCT/EP2022/082281

申请日：2022-11-17

Applicant: INSTITUT CURIE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： CECCALDI, Raphaël ,  MUSIANI, Daniele ,  HATICE, Yucel

IPC: A61K45/06 ,  A61K31/00 ,  A61K31/713 ,  A61P35/00

Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of cancer, particularly BRCA-associated cancer and chemo-resistance BRCA-associated cancer. The inventors investigated the role of NMNAT1 in cancer, particularly in BRCA-associated cancer. The inventors demonstrated that NMNAT1 inhibition kills BRCA1 and BRCA2-mutated tumor cells but does not affect the survival of non-BRCA-mutated cells. The inventors also demonstrated that NMNAT1, a nuclear enzyme other than PARP1, is crucial for the survival of HRD cells and indicate that NMNAT1 is a key factor which activities are necessary for the survival of HRD cells. The inventors also demonstrated that inhibition of NMNAT1 kills PARP-inhibitor and cisplatin-resistant BRCA1 and BRCA2-mutated tumors and show that targeting NMNAT1 kills chemo-resistance HRD cells, particularly PARPi-resistant HRD cells. Altogether, the present invention highlights the role of NMNAT1 inhibitors in cancer and the use of NMNAT1 inhibitors in the treatment of cancer, particularly BRCA-associated cancer including BRCA-associated cancer with acquired drug resistance in mono- or combination therapy with PARPi. In the present invention, the inventors provide in vitro evidences towards a direct role of NMNAT1 in BRCA-associated cancer. Thus, the present invention relates to NMNAT1 inhibitor for use in the treatment of cancer, particularly HRD cancer, BRCA-associated cancer and chemo-resistance BRCA-associated cancer.

公开(公告)号：WO2023006748A1

公开(公告)日：2023-02-02

申请号：PCT/EP2022/070944

申请日：2022-07-26

Applicant: NETRIS PHARMA ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE CLAUDE BERNARD LYON 1 ,  CENTRE LEON BERARD ,  HOSPICES CIVILS DE LYON

Inventor： RICHAUD, Mathieu ,  WISCHHUSEN, Jennifer ,  NEVES, David ,  MEHLEN, Patrick ,  SARRUT, David ,  GIBERT, Benjamin ,  KRYZA, David

IPC: C07K16/22 ,  A61K51/10 ,  A61P35/00

Abstract: The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is also shown herein that Netrin-(1) is expressed very early during tumor formation. This makes Netrin-(1) an unexpected very specific target for imagery and/or targeted therapy. The present invention thus relates to compounds comprising an anti-Netrin-1 antibody, especially NP(137), a chelating moiety, optionally associated with a radioisotope, and their use either in imagery, diagnosis, especially companion diagnosis, or in targeted therapy. New diagnostic tests, which may be companion tests, and new cancer therapies, that may be combined to the companion test, are also proposed.

公开(公告)号：WO2022254023A1

公开(公告)日：2022-12-08

申请号：PCT/EP2022/065222

申请日：2022-06-03

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ D'AIX-MARSEILLE ,  INSTITUT PAOLI-CALMETTES

Inventor： IOVANNA, Juan ,  DUSETTI, Nelson ,  FRAUNHOFFER, Nicolas

IPC: C12Q1/6886

Abstract: The present invention relates to a method and a kit for determining if a patient having pancreatic ductal adenocarcinoma (PDAC) is sensitive to a treatment. It further relates to a method for determining a suitable treatment for a patient having PDAC.

公开(公告)号：WO2022229265A1

公开(公告)日：2022-11-03

申请号：PCT/EP2022/061221

申请日：2022-04-27

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE GRENOBLE ALPES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  HOSPICES CIVILS DE LYON ,  CENTRE LEON BERARD ,  UNIVERSITÉ CLAUDE BERNARD LYON 1

Inventor： SOUCHON, Rémi ,  JAOUEN, Tristan ,  HOANG-DINH, Au ,  GONINDARD, Christelle ,  ROUVIERE, Olivier

IPC: G06T7/00

Abstract: The invention relates to a system and a method for computer-aided detection (CAD) of aggressive prostate cancers. The automatic diagnosis of aggressive prostate cancers is difficult and methods that work with some MRI scanners do not work as well when implemented on images from different scanners. By studying a data base containing MRI data and biopsy results from 265 patients, acquired by 4 different types of MRI scanners, using machine learning techniques, the inventors established a method for automatically determining the presence of aggressive cancers, this methods showing high sensitivity and specificity when implemented on another database containing MRI data from 270 patients, acquired by different MRI scanners than the first database. The method involves feeding MRI images to a system calculating a score for a portion of the prostate and determines that the portion contains an aggressive cancer based on whether a criterion depending on the score is verified.

公开(公告)号：WO2022223693A1

公开(公告)日：2022-10-27

申请号：PCT/EP2022/060554

申请日：2022-04-21

Applicant: ETABLISSEMENT FRANÇAIS DU SANG ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE DE STRASBOURG ,  AVIGNON UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE D'AIX MARSEILLE ,  ECOLE CENTRALE DE MARSEILLE

Inventor： STRASSEL, Catherine ,  MALLO, Léa ,  DO SACRAMENTO, Valentin ,  BERTRAND, Eric ,  KNAPP, Yannick

IPC: C12M1/00

Abstract: L'invention concerne un procédé de libération des plaquettes à partir de mégacaryocytes contenus dans un fluide (F), ledit procédé étant mis en œuvre au moyen d'un système (1) comprenant deux cylindres (11, 13) concentriques, un cylindre intérieur (11) comprenant une paroi (12) cylindrique et un cylindre extérieur (13) creux situé radialement externe par rapport au cylindre intérieur (11), ledit cylindre extérieur (13) comprenant une paroi (14) cylindrique d'une base (13a) au niveau de laquelle ledit deuxième cylindre est fermé, lesdits cylindres (11, 13) étant séparés par un espace (15) dépourvu de toute pièce mécanique, ledit espace (15) étant destiné à recevoir le fluide (F), ledit procédé comprenant les étapes suivantes : (100) alimenter ledit espace (15) avec un fluide (F) comprenant des mégacaryocytes, (200) déplacer le cylindre intérieur (11) en rotation autour de son axe, le cylindre extérieur (13) étant fixe, ou déplacer les deux cylindres (11, 13) en sens inverse autour de leurs axes, de sorte à générer un écoulement de fluide (F) au moins partiellement turbulent dans ledit espace (15) et obtenir un deuxième fluide (F') enrichi en plaquettes.

公开(公告)号：WO2022194926A1

公开(公告)日：2022-09-22

申请号：PCT/EP2022/056809

申请日：2022-03-16

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITÉ D'AIX-MARSEILLE ,  INSTITUT JEAN PAOLI & IRENE CALMETTES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE BORDEAUX

Inventor： ROCCHI, Palma ,  CAMPLO, Michel ,  BARTHELEMY, Philippe ,  ZIOUZIOU, Hajer ,  SIRI, Olivier ,  PARIS, Clément

IPC: A61K9/107 ,  A61K31/498 ,  A61K31/7052 ,  A61P35/00

Abstract: The present invention concerns nanoparticles with a core comprising a phenazine derivative and a shell comprising at least one layer of a nucleolipid, compositions comprising them and their pharmaceutical uses, especially in the prevention and/or treatment of diseases in which the interaction between the proteins Hsp27 and eIF4E is involved.

公开(公告)号：WO2022157199A1

公开(公告)日：2022-07-28

申请号：PCT/EP2022/051140

申请日：2022-01-19

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS ,  UNIVERSITE DE POITIERS ,  SOMNO ENGINEERING SAS

Inventor： DROUOT, Xavier ,  DE LA BELLEISSUE, Maud Nicol

IPC: A61B5/00

Abstract: The present invention relates to poor sleep issues notably in the contact of people fallen in coma. Therefore, it is desirable to be able to monitor sleep in intensive healthcare unit. However, the known methods so far requires the presence of sleep specialists, which renders the use of such monitoring method very difficult to implement. Therefore, the inventors have developed a method and a system with a reduced invasiveness and limited human intervention. The present invention relates to a specific sleep analyzer.

公开(公告)号：WO2022129976A1

公开(公告)日：2022-06-23

申请号：PCT/IB2020/001111

申请日：2020-12-17

Applicant: SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ECOLE NORMALE SUPERIEURE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  COLLEGE DE FRANCE

Inventor： SAGAN, Sandrine ,  JOLIOT, Alain ,  WALRANT, Astrid ,  CARLIER, Ludovic ,  CARDON, Sébastien

IPC: C07K7/00 ,  C07K7/08 ,  G01N33/574 ,  A61K38/00

Abstract: The present invention relates to a polypeptide X1X2-RK-X3X4-KK-X5X6X7X8X9X10-KR-X11X12 (SEQ ID N°1) able to bind selectively to cells expressing proteoglycans comprising glycosaminoglycans as heparin or heparan sulfate. The linkage of said polypeptide to an internalization peptide enables the polypeptide to be internalized. The present invention further relates to a conjugated polypeptide comprising said polypeptide and a biomarker, to a cell penetrating polypeptide comprising said polypeptide, optionally a linker and a cell internalization peptide and a chimeric polypeptide comprising said cell penetrating polypeptide and one or more biological cargos.

公开(公告)号：WO2022123282A1

公开(公告)日：2022-06-16

申请号：PCT/IB2020/001097

申请日：2020-12-08

Applicant: SORBONNE UNIVERSITE [FR]/[FR] ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR]/[FR] ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) [FR]/[FR]

Inventor： ZEITZ, Christina ,  DALKARA, Deniz ,  VARIN, Juliette ,  AUDO, Isabelle ,  PICAUD, Serge ,  SAHEL, José-Alain

IPC: C12N15/864

Abstract: The present invention relates to an expression cassette allowing expression of a functional LRIT3 protein in mammal eyes; said expression cassette is inserted in an expression vector, preferably an adeno-associated virus (AAV); accordingly, the present invention further relates to a recombinant adeno-associated virus (AAV) vector carrying a nucleic acid sequence encoding a normal LRIT3 gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells, a pharmaceutically acceptable composition comprising such a recombinant AAV vector and to its use for the treatment of congenital stationary night blindness.

公开(公告)号：WO2022106714A1

公开(公告)日：2022-05-27

申请号：PCT/EP2021/082619

申请日：2021-11-23

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITÉ DE TOURS ,  UNIVERSITE D'ORLEANS

Inventor： ROUTIER, Sylvain ,  BURON, Frédéric ,  SUZENET, Franck ,  RODRIGUES, Nuno ,  CHALON, Sylvie ,  VERCOUILLIE, Johnny ,  GUILLOTEAU, Denis ,  EMOND, Patrick ,  MARZAG, Hamid

IPC: A61K51/04 ,  A61K101/02 ,  C07B59/00 ,  C07D211/14 ,  C07F5/02 ,  C07F17/00

Abstract: La présente invention concerne le composé radiomarqué de l'énantiomère (R,R) du 5-fluoro-3-4(-phénylpipéridin-1-yl)-1,2,3,4-tétrahydronaphthalèn-2-ol, ainsi que ce composé pour son utilisation dans une méthode de diagnostic in vivo, notamment d'une maladie neurodégénérative cholinergique, par exemple choisie dans le groupe constitué de la maladie d'Alzheimer, de la dysmnésie, du trouble d'apprentissage, de la schizophrénie, du dysfonctionnement cognitif, du trouble d'hyperactivité, de la névrose d'angoisse, de la dépression, de l'analgésie et de la maladie de Parkinson.